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REGULAR ARTICLE
TFPIa interacts with FVa and FXa to inhibit prothrombinase during the
initiation of coagulation
Jeremy P. Wood,1 Helle H. Petersen,2 Bingke Yu,3 Xiaoai Wu,3 Ida Hilden,2 and Alan E. Mast1,4
1Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI; 2Global Research, Novo Nordisk, Maaloev, Denmark; 3Discovery Technology China, Novo Nordisk
Research Center China, Beijing, China; and 4Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI
Key Points
• TFPIa inhibits pro-
thrombinase through
interactions with the
FXa active site and
B-domain acidic region
and heavy chain of
FXa-activated FVa.
• Leu252-Thr255 of the
TFPIa basic region is
necessary for inhibitory
activity but not for
binding the
FXa-activated FVa
acidic region.
Tissue factor pathway inhibitor a (TFPIa) inhibits prothrombinase, the thrombin-
generating complex of factor Xa (FXa) and factor Va (FVa), during the initiation of
coagulation. This inhibition requires binding of a conserved basic region within TFPIa to
a conserved acidic region in FXa-activated and platelet-released FVa. In this study, the
contribution of interactions between TFPIa and the FXa active site and FVa heavy chain
to prothrombinase inhibition were examined to further define the inhibitory
biochemistry. Removal of FXa active site binding by mutation or by deletion of the
second Kunitz domain (K2) of TFPIa produced 17- or 34-fold weaker prothrombinase
inhibition, respectively, establishing that K2 binding to the FXa active site is required for
efficient inhibition. Substitution of the TFPIa basic region uncharged residues (Leu252,
Ile253, Thr255) with Ala (TFPI-AAKA) produced 5.8-fold decreased inhibition. This
finding was confirmed using a basic region peptide (Leu252-Lys261) and Ala substitution
peptides, which established that the uncharged residues are required for
prothrombinase inhibitory activity but not for binding the FVa acidic region. This
suggests that the uncharged residues mediate a secondary interaction with FVa
subsequent to acidic region binding. This secondary interaction seems to be with the
FVa heavy chain, because the FV Leiden mutation weakened prothrombinase inhibition
by TFPIa but did not alter TFPI-AAKA inhibitory activity. Thus, efficient inhibition of
prothrombinase by TFPIa requires at least 3 intermolecular interactions: (1) the
TFPIa basic region binds the FVa acidic region, (2) K2 binds the FXa active site, and
(3) Leu252-Thr255 binds the FVa heavy chain.
Introduction
Prothrombinase, the complex of the serine protease factor Xa (FXa) and its cofactor factor Va (FVa),
generates the thrombin needed to form a blood clot.1,2 FVa is generated through proteolytic activation of
its precursor, FV, which is maintained as an inactive procofactor through interactions between basic and
acidic regions within its activation peptide (B-domain).3-5 Removal of either the acidic or basic region
activates FV to FVa.3,4 FVa generated through limited proteolysis by FXa6 and forms of FVa released
from activated platelets7,8 retain the acidic region, which remains only during the initiation phase of
coagulation, as thrombin catalyzes rapid removal of the entire B-domain.6,9
Forms of prothrombinase containing the FVa acidic region are inhibited by tissue factor pathway inhibitor
a (TFPIa), a trivalent Kunitz-type serine protease inhibitor that regulates the initiation of coagulation.10-13
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However, the biochemical mechanism of this inhibition remains
unclear. TFPIa contains a 9-residue basic sequence in its C-terminal
region (LIKTKRKRK) that is nearly identical to the FV B-domain basic
region (LIKTRKKKK).12 This sequence is conserved in both proteins
across mammals.12,14 The TFPIa basic region tightly binds to the
FVa acidic region12,15,16 in a charge-dependent interaction that is
blocked by negatively charged polymers, such as heparins17,18 and
polyphosphates.12,19,20 TFPIa does not effectively inhibit thrombin
generation by prothrombinase if either the FVa acidic region or TFPIa
basic region is missing.10-12 Because a peptide mimicking the
homologous FV basic region competes against FXa for FVa binding,
it has been proposed that this peptide, and by extension TFPIa,
inhibits thrombin generation by displacing FXa from FVa, thereby
preventing prothrombinase assembly.21
The ability of the FV basic region peptide to compete against
FXa for FVa binding suggests that inhibition by the peptide
involves at least 2 binding sites: (1) a high-affinity interaction with
the FVa acidic region, and (2) a low-affinity interaction with the FVa
heavy chain, which does not occur in the absence of acidic
region binding.12,21 Consistent with this supposition, the FV Leiden
(FVL) mutation (Arg506→Gln in the FVa heavy chain) causes an
approximately twofold decrease in the ability of either TFPIa or the
TFPIa basic region peptide to inhibit prothrombinase containing
the FVa acidic region.22 This small change in inhibitory kinetics
suggests that TFPIamay not bind directly to Arg506, but rather that
its binding site is close enough to Arg506 that accessibility is
affected by this mutation. In addition, poly-L-lysine does not inhibit
prothrombinase activity, demonstrating that the basic residues,
although required, are not sufficient for inhibition.21
Even though the TFPIa and FV basic region peptides bind the FVa
acidic region with low nanomolar affinity, inhibition of thrombin
production requires 2 orders of magnitude higher concentrations of
either peptide than TFPIa.12,21 This discrepancy suggests that the
efficient inhibition achieved by TFPIa requires more than simply the
interaction of the basic C-terminus with FVa. Because the second
Kunitz domain (K2) of TFPIa is a well-described inhibitor of the FXa
active site,23 we hypothesized that this interaction is also required
for prothrombinase inhibition. In the present study, full-length forms
of TFPIa with amino acid substitutions in K2 that prevent binding to
the FXa active site or within the uncharged amino acids of the basic
region, truncated forms of TFPIa, and basic region peptides were
used in purified protein– and plasma-based assays to define the
interactions required for prothrombinase inhibition.
Materials and methods
Proteins
Human FXa, thrombin, prothrombin, and FX were from Enzyme
Research Laboratories (South Bend, IN). Human FV was from
Paula B. Tracy or Kathleen M. Brummel-Ziedins (University of
Vermont, Burlington, VT) and activated with FXa (FVaXa) or thrombin
(FVaIIa).
12 FV810, a recombinant form of FV that retains the TFPIa-
binding acidic region,3,5 and FV810 containing the Leiden
Arg506→Gln substitution (FVL810) were from Rodney M. Camire
(University of Pennsylvania, Philadelphia, PA). TF (Dade Innovin) was
fromSiemens (Washington, DC). Human FVIIa and amouse antibody
against the TFPI K2 domain (anti-K2) were obtained as described.24
A rabbit polyclonal antibody that recognizes the final 12 amino acids
of TFPIa (anti-CTP) was produced by Abcam (Burlingame, CA).
Goat anti-mouse IRDye680 and goat anti-rabbit IRDye800CW were
from LI-COR Biosciences (Lincoln, NE).
Expression and purification of altered TFPIa proteins
The DNA sequences of TFPI were synthesized with CD33 signal
peptide and cloned into vector pJSV002 for mammalian expression.
The genes of TFPIDK2 (Arg107Ala) and TFPI-AAKA (Leu252Ala/
Ile253Ala/Thr255Ala) were constructed based on wild-type TFPIa
by site-directed mutagenesis. Plasmids encoding TFPI variants
were transfected into HEK293-6E cells (1.0 3 106 cells per mL),
with DNA molar ratio of 1:1. Transfection was performed following
the FreeStyle 293 expression manual (Invitrogen). Cells were
harvested for purification 5 days posttransfection.
For TFPIDK2, the supernatant was applied to an anti-TFPI sepharose
affinity column (anti-TFPI antibody coupled to the HiTrap NHS-
activated HP column; GE Healthcare) and equilibrated in phosphate-
buffered saline (PBS). The bound protein was eluted with 0.1 M of
glycine-hydrochloride (HCl), pH 2.8. Fractions were collected and
neutralized immediately with 1/20 volume 2 M of Tris-HCl, pH 9.0, for
further purification. For TFPI-AAKA, the supernatant was applied to a
Heparin Sepharose 6 Fast Flow affinity column (GE Healthcare),
equilibrated in 20 mM of Tris-HCl, pH 7.5. The bound protein was
eluted with a 0.2- to 1-M linear gradient of sodium chloride. Fractions
containing the TFPI variants were collected. The pooled fractions
were further purified by size-exclusion chromatography on a Super-
dex 75 prep grade column (GE Healthcare) in PBS.
His-thioredoxin (Trx)-3C-K3C (TFPIa residues 185-271) was
synthesized and cloned into the pET32a vector. The plasmid was
transformed into Escherichia coli BL21(DE3) host strain and
cultured in terrific broth medium. Expression was induced when
optical density measured at a wavelength of 600 nm reached
0.1, with 0.1 mM of isopropyl-b-D-thiogalactoside. Protein was
expressed overnight at 18°C, and the bacterial pellets were then
harvested for purification. The cell pellets were resuspended in lysis
buffer (50 mM of Tris, pH 8.0, 0.1% Tween-20) and disrupted by
French press. Cell debris was removed by centrifugation. Super-
natant was applied to an Ni-NTA Superflow column (QIAGEN),
equilibrated in 50 mM of Tris, pH 8.0; 4 M of urea; 300 mM of
sodium chloride; and 20 mM of imidazole. The bound protein was
eluted with a 20- to 400-mM linear gradient of imidazole. The pooled
fractions were further purified by cation exchange chromatography
on an SP-HP column (GE Healthcare). Eluted protein was digested
by 3C protease to remove the His-Trx-3C tag. Then, the TFPI
K3C fragment was further purified using an SP-HP column
(GE Healthcare) and buffer exchanged to PBS.
All purified proteins were sterilized by filtration through a 0.2-mm
filter unit (Sartorius). The purity was analyzed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and size-
exclusion high-performance liquid chromatography. The protein
identity was confirmed by mass spectrometry.
Peptides
Peptides were made by the Protein Chemistry Core Laboratory
(BloodCenter of Wisconsin, Milwaukee, WI) or Peptide 2.0
(Chantilly, VA). Peptide concentrations were determined by mea-
surement at 205 nm25 and comparison with a standard curve
generated using a peptide of similar molecular weight and isoelectric
point (GPYVKQNTLKLAT). The concentration of the peptide
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standard was measured at 280 nm (E1%, 10.4). The wild-type peptide
(LIKTKRKRKK) was also synthesized with 2 N-terminal aminohexanoic
acid spacers and 5(6)carboxy-X-rhodamine (Life Technologies, Grand
Island, NY) coupled to the N-terminus (Rhod-LIKTKRKRKK). The
concentration of Rhod-LIKTKRKRKK was determined by measuring the
absorbance at 575 nm (carboxy-X-rhodamine; E1M, 82 000) and at
205 nm, which yielded similar results (190 and 215 mM, respectively).
Phospholipid vesicles
Phospholipid vesicles containing 20% phosphatidylserine, 20%
phosphatidylethanolamine, and 60% phosphatidylcholine were
prepared according to the method of Morrissey.26
Prothrombinase activity assays
FVaXa, FVaIIa, FV810, or FVL810 (0.5 nM) was incubated with
phospholipid vesicles (20 mM), the thrombin inhibitor dansylarginine
N-(3-ethyl-1,5-pentanediyl)amide (DAPA; 3 mM; Haematologic
Technologies, Essex Junction, VT), and varying concentrations of
TFPIa protein or peptide. DAPA was included in these reactions to
limit thrombin-mediated removal of the FVa B-domain acidic region.
Nesheim et al27 demonstrated that the inclusion of DAPA does not
alter the rate of thrombin generation. Reactions were initiated by
addition of prothrombin (1.4 mM) and FXa (5 nM). Aliquots were
removed at timed intervals and quenched with EDTA (33 mM),
diluting DAPA to a final concentration of 0.2 mM. Thrombin was
measured using the chromogenic substrate Spectrozyme TH
(0.32 mM; Sekisui Diagnostics, Lexington, MA). GraphPad Prism
v.6 (GraphPad Software, La Jolla, CA) was used to determine 50%
inhibitory concentrations (IC50s).
12 Assuming Ki 5 0.15 mM for
thrombin inhibition by DAPA,28 and Km 5 2.5 mM for Spectrozyme
TH cleavage by thrombin,29 thrombin is expected to be 99% active
under these conditions.
Calibrated automated thrombography
All experiments using humans were approved by the BloodCenter
of Wisconsin Institutional Review Board. Platelet-rich plasma (PRP)
was prepared from whole blood collected into citrate and corn
trypsin inhibitor (50 mg/mL; Haematologic Technologies). TFPI-
depleted plasma was from Sekisui Diagnostics. Calibrated auto-
mated thrombography assays were performed using a Fluoroskan
Ascent microplate fluorometer (Thermo Scientific), as described.12
Assays using PRP were initiated with FXa (0.1 nM) and collagen
(15 mg/mL). Assays using TFPI-depleted plasma were initiated with
FXa and phospholipid vesicles (4 mM).
FXa activity assays
FXa (0.2 nM) was incubated with varying concentrations of the altered
TFPIa proteins, and cleavage of the chromogenic substrate Spec-
trozyme Xa (0.5 mM; Sekisui Diagnostics) was monitored at 405 nm.
TF-FVIIa activity assays
TF (6 pM) was incubated with phospholipid vesicles (20 mM), FVIIa
(20 pM), and varying concentrations of the altered TFPIa proteins.
Reactions were initiated by addition of FX (20 nM), and cleavage of
Spectrozyme Xa was monitored at 405 nm.
Fluorescence anisotropy
Steady-state fluorescence anisotropywasmeasured in aQuantaMaster
spectrafluorometer (Photon Technology International, Edison, NJ).12
Emission and excitation wavelengths were 580 and 605 nm,
respectively. For direct binding measurements, Rhod-LIKTKRKRKK
(30 nM) was incubated with increasing concentrations of FV810. For
displacement experiments, Rhod-LIKTKRKRKK (30 nM) and FV810
(30 nM) were incubated with increasing concentrations of unlabeled
peptide. Distribution coefficient (Kd) values were obtained from the
direct binding30 and displacement experiments.31
Western blotting
Recombinant TFPIa proteins were diluted into sample preparation
buffer (62.5 mM of Tris, pH 6.8; 10% glycerol; 1% SDS; 0.0005%
Bromphenol Blue), separated by SDS-PAGE on a 4% to 20%
acrylamide gel,32 and transferred to nitrocellulose.33 The blot was
probed with mouse anti-K2 and rabbit anti-CTP (5 mg/mL each),
followed by detection with goat anti-mouse IRDye680 and goat
anti-rabbit IRDye800CW secondary antibodies (1:10 000 dilution
each). The blot was developed using Odyssey Infrared Imager
Running Image Studio v.4.0 (LI-COR Biosciences).
Results
Characterization of recombinant TFPIa proteins
The roles of the TFPIa K2 domain and the uncharged residues
within the TFPIa basic region in prothrombinase inhibition were
examined using altered recombinant TFPIa proteins (Figure 1A).
These proteins included: (1) wild-type TFPIa; (2) 2 altered TFPIa
proteins incapable of binding the FXa active site, TFPIDK2 (Arg107
of K2 mutated to Ala) and K3C, which lacks the K1 and K2
domains; and (3) TFPIa in which the uncharged residues of the
basic region (Leu252, Ile253, Thr255) were substituted with Ala
(TFPI-AAKA). Because the TFPIa C-terminus is susceptible to
proteolysis, the presence of an intact C-terminus was verified by
western blotting with an antibody directed against the final 12
amino acids of TFPIa (Figure 1B). This antibody recognized all of
the recombinant proteins used in these studies, confirming the
presence of an intact C-terminus in each. A recombinant TFPI
containing only the K1 and K2 domains, previously shown to be a
poor inhibitor of prothrombinase,12 was included as a negative
control for the western blot. Similarly, an antibody against the K2
domain (anti-K2) recognized all of the recombinant proteins except
K3C. TFPIa and TFPI-AAKA directly inhibited FXa and also inhibited
TF-FVIIa in assays using purified proteins, confirming the presence
of active K1 and K2 domains (supplemental Figures 1 and 2). K3C
did not inhibit TF-FVIIa or FXa, and TFPIDK2 only weakly inhibited
FXa. The weak FXa inhibition by TFPIDK2 was likely caused by the
functional K1 domain, as demonstrated by Petersen et al.34
Binding of the FXa active site is required for efficient
prothrombinase inhibition
The role of the K2 domain in prothrombinase inhibition was evaluated
using TFPIDK2 and K3C. K3C is incapable of inhibiting the FXa
active site, and TFPIDK2 is a poor FXa inhibitor (supplemental
Figure 1). In purified prothrombinase assays, TFPIDK2 was a 17-fold
weaker inhibitor than wild-type TFPIa (IC50, 30.6vs 1.8 nM), and K3C
was even weaker than TFPIDK2 (IC50, 61.4 nM; Figure 2A).
Consistent with the prothrombinase assays using purified proteins,
TFPIa dose dependently inhibited FXa-initiated thrombin generation
in TFPI-depleted plasma, increasing the lag time by 79.9%6 4.3% at
5 nM and 214.6% 6 20.6% at 10 nM (Figure 2B). TFPIDK2 had
significantly less effect, only increasing the lag time by 45.5%6 8.1%
at 10 nM (P , .0001; Figure 2C). Because activated platelets
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release forms of FVa that bind TFPIa and provide a surface for
prothrombinase assembly, the inhibitory activity of TFPIa variants was
also evaluated in PRP. Although this system is complicated by the
presence of endogenous TFPIa, a similar inhibitory pattern was
apparent. In PRP, 5 nM of TFPIa inhibited FXa-initiated thrombin
generation, delaying the lag time by 31% 6 10% (Figure 2D). In
contrast, thrombin generation was not inhibited by 10 nM of TFPIDK2
(Figure 2E) or K3C (Figure 2F). These results demonstrate that
binding of TFPIa to the FXa active site is required for efficient
prothrombinase inhibition in assays performed using purified proteins
and in assays performed using TFPI-depleted plasma or PRP.
Uncharged residues of the TFPIa basic region are
required for efficient prothrombinase inhibition
We previously showed that the basic residues of the TFPIa basic
region are required for prothrombinase inhibition, because this activity
is blocked by negatively charged molecules, including heparins and
polyphosphates.12,18 However, basic residues are not sufficient
for inhibition, because poly-L-lysine does not block prothrombinase
activity.21 Interestingly, the basic regions of both TFPIa and FV
contain 3 uncharged residues (Leu252, Ile253, and Thr255 in human
TFPIa). These uncharged residues are conserved in both proteins in
mammals, birds, and reptiles (supplemental Figures 3-6). TFPI-AAKA,
in which Leu252, Ile253, and Thr255 are substituted with Ala, was an
intermediate inhibitor of purified prothrombinase (IC50, 10.4 nM)
compared with TFPIa (1.8 nM) and TFPIDK2 (30.6 nM; Figure 3A).
Consistent with the prothrombinase assays using purified proteins,
TFPI-AAKA was a weaker inhibitor of FXa-initiated thrombin
generation in TFPI-depleted plasma (Figure 3B) or PRP (Figure 3C)
than TFPIa. TFPI-AAKA (10 nM) was similar to 5 nM of TFPIa in
delaying the lag time by 34% 6 4%, whereas 5 nM of TFPI-AAKA
delayed the lag time by 17% 6 2%.
The importance of Leu252, Ile253, and Thr255 for prothrombinase
inhibition was more apparent in studies using a TFPIa basic region
peptide (LIKTKRKRKK). Similar to a 26-residue C-terminal peptide
previously characterized,12 LIKTKRKRKK inhibited prothrombinase
assembled with FVaXa (IC50, 1.0 mM) but did not inhibit prothrombi-
nase assembled with FVaIIa (Figure 4A; Table 1) and prolonged the
lag time of FXa-initiated thrombin generation in PRP (Figure 4B).
These results are consistent with inhibition requiring the FVa acidic
region,12,16 which is present in FVaXa but absent from FVaIIa.
6
Substitution of all 3 uncharged residues with Ala (AAKAKRKRKK)
essentially abolished inhibitory activity (Figure 4C; Table 1). Simi-
larly, AAKAKRKRKK did not inhibit thrombin generation in PRP
(Figure 4D). These results demonstrate that the uncharged Leu, Ile,
and Thr amino acids within the TFPIa basic region are required for
efficient prothrombinase inhibition in assays performed using purified
proteins and in assays performed using PRP.
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Figure 1. TFPIa variant proteins used in these studies. (A)
Shown are the domain structures of TFPIa, K1K2 (amino acids
1-160), TFPIDK2 (R107A mutation), TFPI-AAKA (L252A,
I253A, T255A mutations), and K3C (amino acids 185-271). The
3 Kunitz domains are shown in gray. The C-terminal basic
region is blue. (B) Western blot of the TFPI variant proteins,
probed with antibodies against the K2 domain (red) and the last
12 amino acids of the C-terminus (green), with overlay
indicated in yellow. The K1K2 sample contains some dimerized
protein.
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Leu252, Ile253, and Thr255 each contribute to
inhibitory activity
Single Ala substitution peptides were used to examine the individual
contributions of Leu252, Ile253, and Thr255 to the inhibition of
prothrombinase by the TFPIa basic region. Substitution of any of
the 3 uncharged residues resulted in decreased prothrombinase
inhibitory activity (Figure 5A). The Leu252 (AIKTKRKRKK) and
Thr255 (LIKAKRKRKK) substitution peptides had the least in-
hibitory activity (IC50, 70and 110mM, respectively), whereas the
Ile253 substitution peptide (LAKTKRKRKK) retained greater in-
hibitory activity (IC50, 17 mM). None of the single Ala peptides
inhibited thrombin generation in PRP, at concentrations up to
20 mM (Figure 5B-D). Thus, each of these residues individually
contributes to the inhibitory activity of the basic region peptide.
Conserved basic residues mediate FVa binding
Fluorescence anisotropy was used to measure peptide binding to
FV810, a recombinant form of FVa that contains the B-domain
acidic region3,5 and tightly binds TFPIa.12 The Kd of each peptide
for binding FV810 was determined by measuring its ability to
compete against Rhod-LIKTKRKRKK (Kd, 8.6 nM). All of the altered
peptides had similar affinity for FV810, which was not different
than that of LIKTKRKRKK (Figure 6A; Table 1). Thus, the uncharged
residues do not contribute significantly to the binding affinity
for FVa.
Because AAKAKRKRKK binds FV810 similarly to LIKTKRKRKK
(Figure 6A) but does not inhibit prothrombinase activity (Figure 4D),
we hypothesized that AAKAKRKRKK would compete against
LIKTKRKRKK for binding to the FVa acidic region and prevent
prothrombinase inhibition. Purified prothrombinase assays were
performed in the presence of LIKTKRKRKK (3 mM) and increasing
concentrations of AAKAKRKRKK, which reversed prothrombinase
inhibition in a dose-dependent manner (IC50, 6.0 mM; Figure 6B).
Residues Leu252-Thr255 are disrupted by FVL
Because residues Leu252-Thr255 were not necessary for binding
the FVa acidic region but were required for optimal inhibitory
activity, we hypothesized that they may be involved in an interaction
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Figure 2. The K2 domain of TFPIa enhances prothrom-
binase inhibition. (A) FVaXa (0.5 nM) was incubated with
phospholipid vesicles (20 mM), the thrombin inhibitor DAPA
(3 mM), and TFPIa (open circle), TFPIDK2 (open square), or
K3C (filled square). Reactions were initiated by addition of
prothrombin (1.4 mM) and FXa (5 nM). After dilution to reduce
the effect of DAPA, thrombin was quantified by the rate of
cleavage of a chromogenic substrate (0.32 mM). The initial
rate of thrombin generation is shown as a percentage of
control (mean 6 standard deviation; n $ 3). Lines represent
best-fit inhibition curves. (B-F) Thrombin generation was
measured in TFPI-depleted plasma (B-C) or PRP (D-F).
Reactions were initiated with a mixture of FXa (0.1 nM) and
phospholipid vesicles (4 mM) (B-C) or FXa and collagen
(15 mg/mL) (D-F), in the presence of the indicated concentra-
tions of TFPIa (B,D), TFPIDK2 (C,E), or K3C (F). Shown are
the average thrombin generation curves from experiments
performed in triplicate using TFPI-depleted plasma (B-C) or
using PRP from 4 different donors (D-F).
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with the FVa heavy chain and mediate displacement of FXa.
Consistent with this hypothesis, prothrombinase assembled with
FVa Leiden (Arg506Gln) is somewhat less susceptible to inhibition
by TFPIa than wild-type FVa.22 We compared the ability of TFPI-
AAKA to inhibit prothrombinase assembled with either FV810 or
FVL810. Consistent with the experiments using FXa-activated FVa,
TFPI-AAKA was a weak inhibitor of prothrombinase containing
FV810 (IC50, 16.9 nM; 95% CI, 14.9-20.5 nM; Figure 7A).
However, unlike TFPIa, TFPI-AAKA inhibited prothrombinase
containing FVL810 identically to prothrombinase containing
FV810 (IC50, 17.5 nM; 95% CI, 14.6-19.5 nM). In contrast, the
interaction of TFPIa with FXa is unrelated to the effect of FVL,
because TFPIDK2 was a 1.6-fold weaker inhibitor of prothrombi-
nase containing FVL810 (IC50, 46.7 nM; 95% CI, 41.3-52.9 nM)
compared with FV810 (IC50, 27.9 nM; 95% CI, 21.7-35.9 nM),
similar to the 1.7-fold shift observed with TFPIa (Figure 7B).22
Discussion
Inhibition of prothrombinase by TFPIa requires an exosite in-
teraction between the TFPIa basic region and the FVa acidic region.
Multiple lines of evidence support this assertion: (1) in vitro studies
have shown that the TFPIa basic C-terminus binds to forms of FVa
containing the acidic region with high affinity (Kd,;90 pM) but does
not bind to forms of FVa lacking the acidic region12,15; (2) 2 FV
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Figure 4. The uncharged residues are required for
prothrombinase inhibition by a peptide mimicking the
TFPIa basic region. (A) Prothrombinase activity assays were
performed as in Figure 2A using either FVaXa (filled square) or
FVaIIa (open circle) and the indicated concentrations of
LIKTKRKRKK (LIKT). The initial rate of thrombin generation is
shown as a percentage of control (mean 6 standard deviation;
n $ 3). Lines represent best-fit inhibition curves. (B,D)
Thrombin generation was measured in platelet-rich plasma
as in Figure 2D, in the presence of the indicated concentra-
tions of LIKT (B) or AAKAKRKRKK (AAKA) (D). Shown are
average thrombin generation curves from experiments using at
least 3 donors. (C) Prothrombinase activity assays were
performed using FVaXa and the indicated concentrations of
AAKA (open circle). Inhibition of FVaXa prothrombinase by LIKT
(filled square) is reproduced from panel A for reference.
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mutations producing a truncated B-domain that lacks the basic
region but retains the acidic region have been identified16,35; these
forms of FV circulate bound to TFPIa; and (3) plasma concentra-
tions of TFPIa (;1 nM) do not inhibit thrombin generation by
prothrombinase when the TFPIa basic region or the FVa acidic
region is absent.12 In addition, there is evidence suggesting the
TFPIa basic region may bind FVa outside of the B-domain acidic
region. For example, a peptide mimicking the FV B-domain basic
region, which is homologous to the TFPIa basic region, competes
with FXa for binding to FV810.21 Because FXa binds the FVa heavy
chain,36,37 it has been proposed that the basic peptide binds the
FVa heavy chain and inhibits prothrombinase assembly.21 This
mechanism has since been extrapolated to full-length TFPIa, which
is being described as an inhibitor of prothrombinase assembly.38
However, basic region peptides inhibit prothrombinase only at
micromolar concentrations, whereas TFPIa inhibits at low nano-
molar concentrations.12 This is a striking discrepancy, particularly
because the basic region peptides bind the FVa acidic region with
low nanomolar affinity,12 suggesting that structural features of
TFPIa beyond its basic region mediate prothrombinase inhibition.
FXa-activated FVa (used in the activity assays) and FV810 (used for
binding measurements) are chemically dissimilar forms of FV/FVa.
The structural differences between these forms were considered as
an explanation for the discrepancy between the binding affinity and
inhibitory activity observed. This does not seem likely. The major
difference between FXa-activated FVa and FV810 is that the
former contains the B-domain basic region peptide at 0.5 nM
(equimolar concentration to the FVa) that is cleaved from FV when
it is activated by FXa.6 However, micromolar concentrations of
LIKTKRKRKK are required to inhibit prothrombinase containing
FV810,22 similar to prothrombinase containing FXa-activated FVa,
suggesting that nanomolar concentrations of the FV B-domain
basic peptide have little effect on the inhibitory reaction.12 In this
study, 2 additional interactions were identified that greatly increase
the efficiency of prothrombinase inhibition, allowing for inhibition at
low nanomolar concentrations of TFPIa: (1) the TFPIa K2 domain
binds the FXa active site, and (2) residues Leu252-Thr255 of the
TFPIa C-terminus bind the FVa heavy chain.
TFPIa directly inhibits FXa by binding to the FXa active site
through its K2 domain.23 We previously showed that inhibition of
prothrombinase assembled with FXa-activated FVa by TFPIa
occurs at an IC50 2 orders of magnitude lower than inhibition by a
26-residue peptide mimicking the TFPIa C-terminus and proposed
that inhibition requires interactions with both FVa and FXa.12 Here,
the requirement for FXa active site binding was established using 2
altered forms of TFPIa: TFPIDK2, which has an altered K2 domain
that cannot bind FXa, and K3C, which lacks the K2 domain entirely.
These proteins were 20- to 30-fold weaker inhibitors of prothrom-
binase than TFPIa. Therefore, binding to the active site of FXa
increases the efficiency of prothrombinase inhibition by TFPIa.
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Figure 5. Leu252, Ile253, and Thr255 each contribute to
prothrombinase inhibition. (A) Prothrombinase activity was
measured as in Figure 2A, in the presence of the indicated
concentrations of AIKTKRKRKK (AIKT; open diamond),
LAKTKRKRKK (LAKT; open circle), or LIKAKRKRKK (LIKA; filled
triangle). The initial rate of thrombin generation is shown as a
percentage of control (no peptide; mean 6 standard deviation; n $ 3).
Lines represent best-fit inhibition curves. Inhibition of prothrombinase
by LIKTKRKRKK (LIKT; filled square) is reproduced from Figure 3
for reference. (B-D) Thrombin generation was measured in PRP as
in Figure 2D, using the indicated concentrations of AIKT (B),
LAKT (C), or LIKA (D). Shown are the average thrombin generation
curves from experiments using 3 donors.
Table 1. Prothrombinase inhibition by peptide variants
Peptide IC50, mM (95% CI)* Kd (nM 6 SEM)†
LIKTKRKRKK 1.0 (0.4-2.7) 6.0 6 2.5
AAKAKRKRKK .308‡ 5.9 6 2.4
AIKTKRKRKK 70 (60-82) 10.8 6 3.9
LAKTKRKRKK 17 (7.7-36) 16.2 6 6.5
LIKAKRKRKK 110 (89-130) 9.3 6 3.6
CI, confidence interval; SEM, standard error of the mean.
*IC50 values determined by fitting the data presented in Figures 4 and 5 to a 4-parameter
variable slope equation using GraphPad Prism v.6.
†Binding affinities determined by fitting the data presented in Figure 6A, as described by
Marchand et al.31
‡30% inhibition observed at 308 mM of peptide.
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The TFPIa and FV basic regions contain conserved basic and
uncharged residues. The importance of the basic residues is
evident from the ability of negatively charged polymers, such as
heparin, polyphosphate, and fucoidan, to block prothrombinase
inhibition.12,17-20,39 However, the basic residues are not suffi-
cient for inhibitory activity, because poly-L-lysine does not block
prothrombinase assembly or function.21 Here, we establish that the
uncharged residues of the TFPIa basic region (Leu252, Ile253,
Thr255) are required for efficient prothrombinase inhibitory activity
in experiments using recombinant TFPIa with these amino acids
substituted with Ala and several basic region peptides with the
3 amino acids either all or individually substituted with Ala.
Interestingly, even though the uncharged residues are highly
conserved, they did not contribute to the high-affinity interaction
with the FVa acidic region, but they were required for prothrombi-
nase inhibition.
The requirement of the uncharged amino acids for prothrombinase
inhibition suggested that these amino acids may interact with the
FVa heavy chain in a manner that blocks prothrombinase assembly
by blocking the binding of FXa to FVa, as proposed by Bunce
et al.21 Studies with FVL were used to further pursue this possibility.
FVL is the most common genetic risk factor for thrombosis in
whites and consists of the substitution of Arg506 in the heavy chain
with Gln.22 FVL is resistant to proteolysis by activated protein C,
providing 1 biochemical mechanism for the increased prevalence
of thrombosis.40-42 Our laboratory recently found that TFPIa is a
1.7-fold weaker inhibitor of prothrombinase containing FVL810
compared with FV810.22 Similarly, the prothrombinase inhibitory
activity of LIKTKRKRKK was decreased 2.1-fold22 and that of TFPI-
R107A was reduced 1.6-fold when using FVL810. These small
shifts in inhibitory kinetics become physiologically meaningful
under conditions of reduced TFPIa concentration. For example,
the combination of FVL and TFPI haploinsufficiency is lethal in mice,
which die as a result of perinatal thrombosis.43 Because FXa binds
FVa near Arg506,44-47 it was plausible that the uncharged amino
acids within the TFPIa basic region also bind near Arg506, perhaps
explaining the decreased inhibitory activity toward FVL. Therefore,
experiments were performed to examine the ability of the different
altered forms of TFPIa to inhibit prothrombinase assembled with
FVL. Unlike TFPIa, the inhibitory activity of TFPI-AAKA was not
affected by FVL, a finding consistent with the uncharged amino
acids interacting with the FVa heavy chain. The small shift in kinetics
suggests that this interaction is near, but may not directly involve,
Arg506.
Collectively, these findings can be described using a model where
TFPIa inhibits prothrombinase via at least 3 biochemical interactions:
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(1) the TFPIa basic region binds the FVa acidic region in a charge-
dependent interaction that is mediated by the respective basic and
acidic residues; (2) amino acids Leu252-Thr255 interact with the
FVa heavy chain in the vicinity of Arg506, either preventing FXa from
binding FVa or causing it to bind in a manner that does not promote
thrombin generation; and (3) the K2 domain of TFPIa binds the FXa
active site. These interactions might occur in any order, although it
seems most plausible that TFPIa binds to the FVa acidic region before
the heavy chain, because the latter is a low-affinity interaction. This
model explains the discrepancy between the high affinity and low
inhibitory activity of the TFPIa and FV basic region peptides. Although
these peptides are able to bind the FVa acidic region and heavy chain
and block prothrombinase assembly, they do not block the FXa active
site. High concentrations of peptide are required to push the
equilibrium such that no FXa can bind and thus no activity can be
measured. The model also explains why poly-L-lysine has no inhibitory
activity,21 because it does not contain the Leu, Ile, and Thr residues and
therefore would not interact with the FVa heavy chain and displace FXa.
This model is limited because it does not include other described
mechanisms for how TFPIa may alter prothrombinase activity. It was
recently reported that TFPIa, as well as a peptide mimicking the
TFPIa C-terminus, inhibits thrombin-mediated cleavage of FV at
Arg1545.48 This inhibition is proposed to be the result of steric
hindrance (ie, that the acidic region is close enough to Arg1545 such
that when TFPIa or the peptide is bound to the B-domain, thrombin
cannot access the cleavage site). Thus, TFPIa not only reduces
thrombin generation through inhibition of prothrombinase assembly
and activity, but also reduces the feedback activity of thrombin by
blocking further FVa processing. Similarly, TFPIa may alter cleavage
of FVa at Arg506 by activated protein C49 or at Arg510 by factor
XIa,50 because the TFPIa basic region binds near these sites.
In summary, TFPIa inhibits prothrombinase activity through the
combination of disrupting prothrombinase assembly and blocking the
FXa active site. This inhibition is mediated by the C-terminal basic
region and the K2 domain. The basic and uncharged amino acids of
theC-terminal region serve distinct roles in the inhibitory biochemistry.
Each of these 3 interactions increases the efficiency of prothrombi-
nase inhibition by TFPIa. Therefore, all 3 are likely required for
prothrombinase inhibition under physiological conditions.
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42. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;
343(8912):1536-1538.
26 DECEMBER 2017 x VOLUME 1, NUMBER 27 TFPIa INHIBITION OF PROTHROMBINASE 2701
.For personal use onlyon April 10, 2019. by guest  www.bloodadvances.orgFrom 
43. Eitzman DT, Westrick RJ, Bi X, et al. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency
and factor V Leiden. Circulation. 2002;105(18):2139-2142.
44. Gale AJ, Yegneswaran S, Xu X, Pellequer JL, Griffin JH. Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C
cleavage site. J Biol Chem. 2007;282(30):21848-21855.
45. Nesheim ME, Canfield WM, Kisiel W, Mann KG. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C.
J Biol Chem. 1982;257(3):1443-1447.
46. Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and
factor VaR506Q by activated protein C. J Biol Chem. 1995;270(46):27852-27858.
47. Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa
protection. J Biol Chem. 1988;263(29):14884-14890.
48. van Doorn P, Rosing J, Wielders SJ, Hackeng TM, Castoldi E. The C-terminus of tissue factor pathway inhibitor-a inhibits factor V activation by protecting
the Arg(1545) cleavage site. J Thromb Haemost. 2017;15(1):140-149.
49. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem. 1995;270(8):4053-4057.
50. Whelihan MF, Orfeo T, Gissel MT, Mann KG. Coagulation procofactor activation by factor XIa. J Thromb Haemost. 2010;8(7):1532-1539.
2702 WOOD et al 26 DECEMBER 2017 x VOLUME 1, NUMBER 27
.For personal use onlyon April 10, 2019. by guest  www.bloodadvances.orgFrom 
